LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Elenco Azioni・BioNTech SE ADR

BioNTech SE ADR

Chiusa

SettoreSettore sanitario

89.38 1.11

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

87.99

Massimo

91.01

Metriche Chiave
By Trading Economics
Entrata	-239M -541M
Vendite	-779M 120M
EPS	-1.95
Margine di Profitto	-450.381
Dipendenti	7,807
EBITDA	-481M -549M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+50.9% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.9B 23B
Apertura precedente	88.27
Chiusura precedente	89.38

Notizie sul Sentiment di mercato

By Acuity

17%

83%

30 / 344 Classifica in Healthcare

BioNTech SE ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 mag 2026, 18:12 UTC

Utili

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mag 2026, 13:54 UTC

Utili

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

10 mar 2026, 12:50 UTC

Utili

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

10 mar 2026, 11:18 UTC

Utili

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

4 ago 2025, 14:14 UTC

Utili

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped. -- Barrons.com

4 ago 2025, 11:59 UTC

Utili

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

12 giu 2025, 14:20 UTC

Acquisizioni, Fusioni, Takeovers

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 giu 2025, 13:34 UTC

Azioni calde

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

10 giu 2025, 12:18 UTC

Utili

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Confronto tra pari

Modifica del prezzo

BioNTech SE ADR Previsione

Obiettivo di Prezzo

By TipRanks

50.9% in crescita

Previsioni per 12 mesi

Media 133.47 USD 50.9%

Alto 167 USD

Basso 94 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per BioNTech SE ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

18 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 18 che hanno fornito valutazioni azionarie a BioNTech SE ADR - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

30 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac